Sentinox for COVID-19: real-time analysis

Download Image

Post

c19early.org

Sentinox for COVID-19

1 study with 39 patients

Serious outcome risk

Sentinox

Control

Significantly lower risk for viral clearance.

COVID-19 Sentinox studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)37%

Viral clearance (1)29%

RCTs (1)37%

Early (1)37%

00.511.5+

← Sentinox
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


May 12 2022	Panatto et al., Viruses, doi:10.3390/v14051033	Efficacy of the Sentinox Spray in Reducing Viral Load in Mild COVID-19 and Its Virucidal Activity against Other Respiratory Viruses: Results of a Randomized Controlled Trial and an In Vitro Study
May 12 2022	29% improved viral clearance (p=0.01). RCT 57 mild COVID-19 patients showing non-significant viral load reduction with Sentinox (STX), a hypochlorous acid nasal spray. The proportion of COVID negative patients by day 5 was significantly higher in the STX-3 group than controls...